Clinical Trial Listing

Below are the clinical trials we are currently offering at Banner MD Anderson Cancer Center. Please continue to check back as we will continue to add additional trials to this list.

If you are interested in participating in any of these trials, please call (480) 256-6444.

For more information about these trials please visit ClinicalTrials.gov.

Brain Cancer

Breast Cancer

A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, hormone Receptor-Positive and HER2/neu Negative Breast Cancer (NCT 01674140)
Principal Investigator: Dr. Mary Cianfrocca

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (NCT03155997)
Principal Investigator: Dr. Lida Mina

A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (NCT02032823)
Principal Investigator: Dr. Shakeela Bahadur

A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment (NCT03056755)
Principal Investigator: Dr. Shakeela Bahadur

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease (NCT02981303)
Principal Investigator: Dr. Lida Mina

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE) (NCT03330847)
Principal Investigator: Dr. Shakeela Bahadur

Effect of Preoperative Breast MRI on Surgical Outcomes, Cost and Quality of Life of Women with Breast Cancer (NCT01805076) 
Principal Investigator: Dr. Julie Billar

A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer (NCT03493854)
Principal Investigator: Dr. Lida Mina

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice (NCT03253575)
Principal Investigator: Dr. Madappa Kundranda

A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer (NCT03499353)
Principal Investigator: Dr. Lida Mina

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT01872975)
Principal Investigator: Dr. Emily Grade

Gastrointestinal Cancer (Pancreatic, Colorectal, Gastric, Liver, Biliary and Neuroendocrine Cancers)

Biliary Cancer

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy (NCT03093870)
Principal Investigator: Dr. Madappa Kundranda

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors (NCT02587962)
Principal Investigator: Dr. Tomislav Dragovich 

Colorectal Cancer

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) (NCT01349881)
Principal Investigator: Dr. Tomislav Dragovich 

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors (NCT02587962)
Principal Investigator: Dr. Tomislav Dragovich 

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice (NCT03253575)
Principal Investigator: Dr. Madappa Kundranda

Gastric Cancer

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors (NCT02587962)
Principal Investigator: Dr. Tomislav Dragovich 

Liver Cancer 

A Phase III, Open-label, randomized study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma (NCT03434379)
Principal Investigator: Dr. Madappa Kundranda

REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma (NCT03289273)
Principal Investigator: Dr. Boris Naraev

Neuroendocrine Tumors

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors (NCT02709889)
Principal Investigator: Dr. Jiaxan Niu 

Pancreatic Cancer

"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma" (NCT02715804)
Principal Investigator: Dr. Tomislav Dragovich

A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma (NCT02993731)
Principal Investigator: Dr. Madappa Kundranda

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (NCT02923921)
Principal Investigator: Dr. Tomislav Dragovich

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously with or without Gemcitabine as 2nd/3rd line therapy in Advanced Pancreatic Cancer Patients (NCT02650804)
Principal Investigator: Dr. Madappa Kundranda

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma (NCT03377491)
Principal Investigator: Dr. Tomislav Dragovich

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy (NCT02184195)
Principal Investigator: Dr. Tomislav Dragovich

Solid Tumor

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors (NCT02587962)
Principal Investigator: Dr. Tomislav Dragovich

Genitourinary Cancer (Bladder and Prostate Cancers)

Gynecologic Cancer (Cervical and Ovarian Cancers)

Head and Neck Cancer

Kidney Cancer

Leukemia

Lung Cancer

A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (NCT02964013) 
Principal Investigator: Dr. Jiaxin Niu

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors (NCT03179436) 
Principal Investigator: Dr. Jiaxin Niu

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Nonsmall Cell Lung Cancer (NSCLC) (NCT03164772)
Principal Investigator: Dr. Jiaxin Niu

A Multicenter, Two-Part, Phase 2 Clinical Study of CMP-001 in Combination with atezolizumab with and without radiation therapy in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03438318)
Principal Investigator: Dr. Jiaxin Niu

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice (NCT03253575)
Principal Investigator: Dr. Madappa Kundranda

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) (NCT03425643)
Principal Investigator: Dr. Qing Zhao

Lymphoma

Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) retinamide, 4-HPR) Emulsion for Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) (NCT02495415) 
Principal Investigator: Dr. Javier Munoz

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL) (NCT01994382)
Principal Investigator: Dr. Javier Munoz

A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies (NCT02343120)
Principal Investigator: Dr. Javier Munoz 

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102) (NCT03039114)
Principal Investigator: Dr. Javier Munoz 

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) (NCT03391466) 
Principal Investigator: Dr. Javier Munoz

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) (NCT03483103)
Principal Investigator: Dr. Javier Munoz

Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T Cell Receptors (CD16V-41BB-CD3ζ), in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma (NCT02776813)
Principal Investigator: Dr. Javier Munoz

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2) (NCT02601313)
Principal Investigator: Dr. Javier Munoz

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (NCT03105336)
Principal Investigator: Dr. Javier Munoz

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma (NCT03677141)
Principal Investigator: Dr. Javier Munoz

Melanoma

Radiation Oncology

Breast Cancer

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT1872975)
Principal Investigator: Dr.Emily Grade

Bone Metastases

A randomized trial evaluating rapid delivery of dose escalated hypofractionated radiotherapy for patients diagnosed with bone metastases for effective palliation of
symptoms
(NCT02163226)
Principal Investigator: Dr.Gary Walker

Prostate Cancer

Prospective Data Registry and Quality of Life Assessment of Men Undergoing High Dose Rate Brachytherapy of the Prostate Using Real-Time Ultrasound Planning 
Principal Investigator: Dr. Anna Likhacheva

Prospective Evaluation of Men Undergoing Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Principal Investigator: Dr. Terrance Roberts

Rectal Cancer

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (NCT02921256)
Principal Investigator: Dr. Jiaxan Niu

Skin Cancer

Skin Surface Brachytherapy for Non-Melanoma Skin Cancers: Prospective Data Registry and Quality of Life Assessment
Principal Investigator: Dr. Anna Likhacheva

Solid Tumor